当前位置:
X-MOL 学术
›
Clin. Transl. Immunol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
p.P476S mutation of RBPJL inhibits the efficacy of anti‐PD‐1 therapy in oesophageal squamous cell carcinoma by blunting T‐cell responses
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-09-16 , DOI: 10.1002/cti2.1172 Lei Miao 1, 2 , Xiao-Li Wei 1, 3 , Qi Zhao 1 , JingJing Qi 1 , Chao Ren 3 , Qi-Nian Wu 1, 4 , Da-Liang Wei 1 , Jia Liu 1 , Feng-Hua Wang 1 , Rui-Hua Xu 1, 5
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-09-16 , DOI: 10.1002/cti2.1172 Lei Miao 1, 2 , Xiao-Li Wei 1, 3 , Qi Zhao 1 , JingJing Qi 1 , Chao Ren 3 , Qi-Nian Wu 1, 4 , Da-Liang Wei 1 , Jia Liu 1 , Feng-Hua Wang 1 , Rui-Hua Xu 1, 5
Affiliation
Anti‐PD‐1 immune checkpoint blockade represents the onset of a new era in cancer immunotherapy. However, robust predictors are necessary for screening patients with immune checkpoint‐responsive oesophageal squamous cell carcinoma (ESCC).
中文翻译:
RBPJL 的 p.P476S 突变通过减弱 T 细胞反应来抑制抗 PD-1 治疗食管鳞状细胞癌的疗效
抗 PD-1 免疫检查点阻断代表了癌症免疫治疗新时代的开始。然而,强大的预测因子对于筛查免疫检查点反应性食管鳞状细胞癌 (ESCC) 患者是必要的。
更新日期:2020-09-18
中文翻译:
RBPJL 的 p.P476S 突变通过减弱 T 细胞反应来抑制抗 PD-1 治疗食管鳞状细胞癌的疗效
抗 PD-1 免疫检查点阻断代表了癌症免疫治疗新时代的开始。然而,强大的预测因子对于筛查免疫检查点反应性食管鳞状细胞癌 (ESCC) 患者是必要的。